UroGen Pharma Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, UroGen Pharma stock has a consensus rating of "Strong Buy" and an average price target of $60. The average 1-year stock price forecast is 79.21% higher than the current stock price, while the lowest is $48 (+43.37%) and the highest is $75 (+124.01%).

Price Target: $60 (+79.21%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$48	$60	$59	$75
Change	+43.37%	+79.21%	+76.22%	+124.01%

Analyst Ratings

The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	May '26	Jun '26	Jul '26	Aug '26	Sep '26	Oct '26
Strong Buy	6	6	6	6	6	6
Buy	1	1	1	1	1	1
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Leland Gershell Oppenheimer	Oppenheimer	Buy Reiterates $60	Buy	Reiterates	$60	+79.21%	Oct 28, 2026
Michael Schmidt Guggenheim	Guggenheim	Buy Maintains $58	Buy	Maintains	$58	+73.24%	Oct 20, 2026
Ram Selvaraju H.C. Wainwright	H.C. Wainwright	Buy Reiterates $75	Buy	Reiterates	$75	+124.01%	Oct 19, 2026
Paul Choi Goldman Sachs	Goldman Sachs	Hold Maintains $44 → $48	Hold	Maintains	$44 → $48	+43.37%	Aug 6, 2026
Tara Bancroft TD Cowen	TD Cowen	Buy Reiterates $50 → $60	Buy	Reiterates	$50 → $60	+79.21%	Aug 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

322.20M

from 109.79M

193.48%

from 109.79M

Revenue Next Year

531.61M

from 322.20M

64.99%

from 322.20M

EPS This Year

-0.24

from -3.19

EPS Next Year

2.59

from -0.24

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	48.04M	64.36M	82.71M	90.40M	109.79M	322.20M
Revenue Growth	307.17%	33.96%	28.52%	9.29%	21.45%	193.48%
Gross Profit	42.89M	56.70M	73.35M	81.52M	97.34M	290.63M
Gross Margin	89.27%	88.11%	88.68%	90.18%	88.66%	90.20%
Operating Income	-92.29M	-79.04M	-65.54M	-95.68M	-124.86M	24.79M
Net Income	-110.82M	-109.78M	-102.24M	-126.87M	-153.49M	-9.27M
EPS	-	-	-	-	-3.19	-0.24
Free Cash Flow	-	-	-	-	-162.73M	8.05M
No. Analysts	-	-	-	-	-	8

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	336.2M
Avg	322.2M
Low	302.0M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	206.2%
Avg	193.5%
Low	175.1%

EPS Forecast

Chart

EPS	2026	2027	2028
High	0.20
Avg	-0.24
Low	-0.83

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-